U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H12N2O2.ClH.H2O
Molecular Weight 282.723
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of OZAGREL HYDROCHLORIDE MONOHYDRATE

SMILES

O.Cl.OC(=O)\C=C\C1=CC=C(CN2C=CN=C2)C=C1

InChI

InChIKey=OWIZTYOMGVTSDP-TXOOBNKBSA-N
InChI=1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H12N2O2
Molecular Weight 228.2466
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P24557|||Q8IUN1|||Q9HD82
Gene ID: 6916.0
Gene Symbol: TBXAS1
Target Organism: Homo sapiens (Human)
11.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DOMENAN

Approved Use

Unknown
Primary
XANBON

Approved Use

Cerebral vasospasm and ischaemia following surgical management of subarachnoid haemorrhage.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
97 ng/mL
1 μg/kg/min single, intravenous
dose: 1 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1657.3 ng/mL
15 μg/kg/min single, intravenous
dose: 15 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
576.5 ng/mL
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1928.8 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2020 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1940 ng/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
281 ng × h/mL
1 μg/kg/min single, intravenous
dose: 1 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4659.2 ng × h/mL
15 μg/kg/min single, intravenous
dose: 15 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
197.4 ng × h/mL
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3913.2 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3360 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3500 ng × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.79 h
1 μg/kg/min single, intravenous
dose: 1 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.66 h
15 μg/kg/min single, intravenous
dose: 15 μg/kg/min
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.09 h
5 mg single, intravenous
dose: 5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.45 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.74 h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.76 h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OZAGREL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
OZAGREL serum
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Thromboxane synthase mutations in an increased bone density disorder (Ghosal syndrome).
2008-03
Effect of sodium ozagrel on the activity of rat CYP2D6.
2007-11-14
Heparin-protamine complexes cause pulmonary hypertension in goats.
1995-10
Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.
1990-12
Patents

Sample Use Guides

1 tablet (200 mg of the active ingredient) at a time, twice a day after breakfast and before bedtime (for asthma). Intravenous infusion of 80mg, twice a day, solute in 500ml normal saline or 5% glucose solution (cerebral vasospasm).
Route of Administration: Other
The influence of ozagrel on platelets aggregation was investigated. Platelet aggregation which was induced by ADP (5 uM) was inhibited by ozagrel. This inhibition was dependent on the concentration of the drug and was significant at 10(−6)–10(−3) M.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:27:26 GMT 2025
Edited
by admin
on Mon Mar 31 21:27:26 GMT 2025
Record UNII
C0I3AF4OHV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OZAGREL HYDROCHLORIDE MONOHYDRATE
Common Name English
OZAGREL HYDROCHLORIDE HYDRATE
JAN  
Preferred Name English
OZAGREL HYDROCHLORIDE HYDRATE [JAN]
Common Name English
2-PROPENOIC ACID, 3-(4-(1H-IMIDAZOL-1-YLMETHYL)PHENYL)-, HYDROCHLORIDE, HYDRATE (1:1:1)
Common Name English
Code System Code Type Description
SMS_ID
100000177063
Created by admin on Mon Mar 31 21:27:26 GMT 2025 , Edited by admin on Mon Mar 31 21:27:26 GMT 2025
PRIMARY
EPA CompTox
DTXSID30232877
Created by admin on Mon Mar 31 21:27:26 GMT 2025 , Edited by admin on Mon Mar 31 21:27:26 GMT 2025
PRIMARY
CAS
83993-01-5
Created by admin on Mon Mar 31 21:27:26 GMT 2025 , Edited by admin on Mon Mar 31 21:27:26 GMT 2025
GENERIC (FAMILY)
FDA UNII
C0I3AF4OHV
Created by admin on Mon Mar 31 21:27:26 GMT 2025 , Edited by admin on Mon Mar 31 21:27:26 GMT 2025
PRIMARY
PUBCHEM
5282439
Created by admin on Mon Mar 31 21:27:26 GMT 2025 , Edited by admin on Mon Mar 31 21:27:26 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY